Strong Financial Performance: Cencora reported a consolidated revenue of $80.7 billion for Q3 FY2025, representing a 9% year-over-year increase. Adjusted diluted EPS grew 20%, reflecting the company¡¯s strong operational execution and improved margins, particularly in the U.S. Healthcare Solutions segment.

U.S. Healthcare Solutions Segment Growth: The U.S. segment saw revenue growth of 9% to $72.9 billion and operating income surged 29% to $902 million. The strong performance was driven by an increase in GLP-1 product sales, but there were some contributions from loss of a low-margin grocery customer and a deceleration in growth for GLP-1s, suggesting future revenue moderation.

International Segment Challenges: The International Healthcare Solutions segment had a revenue increase of 11% (up 9% on a constant currency basis) but faced a 13% decrease in operating income. This was mainly due to softness in global specialty logistics and the consulting business, highlighting ongoing challenges in the international landscape.